Successful End of Ph 2 Meeting with US FDA on Ph 3 Registrational Study Design for PT-112 in Patients with Metastatic CRPC Announced May 21, 2025
GTB-3650 Ph 1 Trial Advanced to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals May 21, 2025
Ph 2 Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection initiated in metastatic CRPC May 13, 2025
First Patient Dosed in STARt-002 Trial of Invikafusp Alfa in Combination with Trodelvy® in Metastatic Breast Cancer May 13, 2025
First patient dosed in the randomized Ph 1/2 study of roginolisib in combination with dostarlimab with or without docetaxel, in advanced NSCLC patients May 13, 2025
Next phase of clinical development for cemsidomide to be enabled with new studies expected to initiate in early 2026 May 13, 2025
Plans for Ph 3 1L vepdegestrant combo trial with atirmociclib and Ph 3 2L combination trial with a CDK4/6 inhibitor shelved May 6, 2025
CAPItello-280 Ph 3 trial of Truqap (capivasertib) + docetaxel and ADT in patients with metastatic CRPC to be discontinued May 6, 2025
Ph 1 study targeting GPC3 with 225Ac-GPC3 (BAY 3547926) in patients with advanced HCC initiated May 6, 2025
Second Interim Analysis of OBI-822 Ph 3 Trial Completed and Trial Termination announced April 30, 2025
Strategic Pipeline Prioritization Announced with Focus on CB-010 and CB-011 Oncology Programs April 30, 2025
Sarah Cannon Research Institute at Colorado Blood Cancer Institute Announced as Key Clinical Trial Site for Ph 1 Trial of CER-1236 in AML April 30, 2025
Ph 1/2a CARMA study of ELC-301 continues as planned following the safety committee’s assessment of cohort 1 April 22, 2025
Clinical development of nemvaleukin to discontinue following review of data from Ph 2 ARTISTRY-6 and Ph 3 ARTISTRY-7 trials April 22, 2025
First Patient Treated in Ph 1 Trial of PHST001 for Patients with Advanced Solid Tumors April 22, 2025
Enrollment completed in Ph 2 CRDF-004 Trial of Onvansertib in 1L RAS-mutated Metastatic CRC April 22, 2025
